(2R)-2-azaniumyl-2-thiophen-3-ylacetate | 1194-86-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-2-azaniumyl-2-thiophen-3-ylacetate
• CAS: 1194-86-1
• 化学式: C6H7NO2S
• 分子量: 157.19
• InChiKey: BVGBBSAQOQTNGF-RXMQYKEDSA-N

物化性质

• 熔点：
  218℃
• 沸点：
  317.5±32.0 °C(Predicted)
• 密度：
  1.418

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  91.6
• 氢给体数：
  2
• 氢受体数：
  4

制备方法与用途

应用范围广泛，D-β-(3-硫杂环己基)-甘氨酸是一种氨基酸衍生物，据文献记载，它可用于合成多粘菌素衍生物及 MMP-13 抑制剂。

文献信息

• RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：The Johns Hopkins University

  公开号：US20210094933A1

  公开（公告）日：2021-04-01

  The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

  本公开提供了受免疫蛋白配体家族FK506和雷帕霉素天然产物启发的大环化合物。生成包含FK506和雷帕霉素结合结构域的Rapafucin大环化合物库，应具有作为治疗疾病新药的潜力。
• Structural insights of sulfonamide-based NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization
  作者：Yiming Xu、Matteo Scipioni、Hallie Blevins、Shijun Zhang

  DOI：10.1007/s00044-020-02692-4

  日期：2021.2

  and amide domain of YQ-II-128 are important for the observed inhibitory potency on the NLRP3 inflammasome. The results also identified the amide domain to incorporate polar moieties to improve solubility and potentially pharmacokinetic properties. As a result, analog 10 was identified as a selective NLRP3 inhibitor with comparable potency while significantly improved aqueous solubility. Collectively

  NLRP3炎性小体作为一种潜在的可治疗靶标，最近已引起人们的广泛关注，以开发针对炎症和神经退行性疾病的潜在疗法。在我们的继续研究中，结构与活性之间的关系研究是基于我们实验室新鉴定的NLRP3抑制剂YQ-II-128进行的，以了解其结构特征并改善水溶性。结果表明，YQ-II-128的丙氧基和酰胺结构域的空间相互作用对于观察到的对NLRP3炎性小体的抑制能力很重要。该结果还确定了酰胺结构域结合了极性部分以改善溶解度和潜在的药代动力学性质。结果，模拟量10被鉴定为具有相当效力的选择性NLRP3抑制剂，同时显着改善了水溶性。总的来说，这些发现强烈鼓励进一步优化10种药物以开发具有改善的药代动力学特性的类似物，作为潜在的NLRP3靶向治疗剂。
• Rapafucin derivative compounds and methods of use thereof
  申请人：The Johns Hopkins University

  公开号：US11066416B2

  公开（公告）日：2021-07-20

  The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

  本公开提供了受天然产物 FK506 和雷帕霉素的免疫嗜蛋白配体家族启发的大环化合物。由含有 FK506 和雷帕霉素结合结构域的大环化合物组成的雷帕霉素库，作为开发用于治疗疾病的药物的新线索，具有巨大的潜力。
• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20060293345A1

  公开（公告）日：2006-12-28

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 inhibitors.
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.